Active Ingredient History

  • Now
Frovatriptan succinate (trade name Frova) is a selective 5-hydroxytryptamine1 (5-HT1B/1D) receptor subtype agonist, and is used for the treatment of migraine attacks with or without aura in adults. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Serious but rare cardiac events have been reported in patients with risk factors predictive of coronary artery disease (CAD). These include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$6.9878 - $102.4829
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole | allegro | frova | frovatriptan | frovatriptan succinate | frovatriptan succinate hydrate | frovelan | migard | mylatrip | (r)-frovatriptan | sb 209509 | sb-209509ax | sb-209509-ax | vml251 | vml-251


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue